Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Press Release :
Increased Prevalence of the Infection Drives Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
The global pipeline analysis of hospital acquired pneumonia drugs market is driven by the rising incidences of nosocomial pneumonia or Hospital-acquired pneumonia.
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is one of the leading reasons for mortality and morbidity despite the existence of improved supportive care, antimicrobial, and prevention therapy.
Hospital-acquired pneumonia or nosocomial pneumonia is any pneumonia that is acquired by a patient in the settings of a hospital at least after 48 to 72 hours of being admitted. It is, as such, is much different from community-acquired pneumonia. Generally, bacterial infection rather than a viral one causes hospital-acquired pneumonia. A patient suffering from hospital-acquired pneumonia usually exhibits a combination of leukocytosis or leucopenia, poor oxygenation, hypothermia or fever, and augmented tracheal secretions.
Multidrug Resistance of Hospital-acquired Pneumonia Causing Bacteria Fuels Growth
Nosocomial or hospital acquired pneumonia gives rise to several complications and create complicate the medical condition for patients admitted in hospitals across the globe. Multidrug resistant microorganisms are responsible for the occurrence of these infections. These infections considerably diminish the patient’s ability to recuperate and numerous comorbidities also follow, which is likely to support growth of the global pipeline analysis of hospital acquired pneumonia drugs market in the years to come.
Some of the symptoms of hospital-acquired pneumonia comprise the following
- A cough with pus-like or greenish phlegm (sputum)
- Chills and fever
- Loss of appetite
- Vomiting and nausea
- Sharp pain in the chest pain that gets worse with deep breathing or coughing
- Shortness of breath
- General discomfort, uneasiness, or ill feeling (malaise)
- Fast heart rate and decreased blood pressure and
These organisms, being multidrug resistant, are immune to the usual antibiotics. Multidrug resistance makes it difficult for the conventional antibiotics to treat the infection acquired in the hospital, which is expected to boost the global pipeline analysis of hospital acquired pneumonia drugs market. Pneumonia is considered one of the most prominent infections caused in the premises of a hospital. Incidences of hospital-acquired pneumonia are quite high in the elderly and infant patients, immunocompromised patients. It also attacks patients going through enteral feeding and in post surgical infections.
Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.
Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs.
Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy.
Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees.
Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.
To gain a complete market understanding, Porters Five Force’s analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market.
Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.
The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.